Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12234588 | 0.92 | GPR119 (0.43) | GPR119CYP1A2CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL12234551 | 0.90 | GPR119 (0.49) | GPR119CYP1A2CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL1550661 | 0.86 | GPR119 (0.43) | GPR119CYP1A2CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL12234558 | 0.84 | GPR119 (0.40) | GPR119KCNH2SCD | |
| SCHEMBL12234549 | 0.81 | GPR119 (0.44) | GPR119CYP1A2CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL2544983 | 0.79 | GPR119 (0.43) | GPR119CYP1A2CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL2539382 | 0.78 | GPR119 (0.56) | GPR119CYP1A2CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL14237536 | 0.78 | SCD (0.42) | GPR119KCNH2SCD | |
| SCHEMBL12234567 | 0.76 | GPR119 (0.40) | GPR119KCNH2SCD | |
| SCHEMBL12234536 | 0.75 | GPR119 (0.53) | GPR119KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131074-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-8372837-B2 | Pyridone and pyridazone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110263548-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131074-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR4, GPR3 | GPR119 1/4885CYP1A2 1042/4885CYP2C19 525/4885 |
| US-20110263548-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR4, GPR3 | GPR119 1/4885CYP1A2 1065/4885CYP2C19 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.